Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
D015250:Aclarubicin; D000880:Anthraquinones / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy; D002360:Carubicin / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use / Q000633:toxicity; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D004341:Drug Evaluation; D015251:Epirubicin; D006321:Heart / Q000187:drug effects; D006801:Humans; D015255:Idarubicin; D007938:Leukemia / Q000188:drug therapy; D017290:Menogaril; D008942:Mitoxantrone; D009279:Naphthacenes / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D009621:Nogalamycin / Q000031:analogs & derivatives / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015251:Epirubicin; D015250:Aclarubicin; D004317:Doxorubicin; D017290:Menogaril; D008942:Mitoxantrone; C027260:pirarubicin; D002360:Carubicin; D009621:Nogalamycin; C030851:esorubicin; D015255:Idarubicin; D003630:Daunorubicin